Transmembrane estrogen receptor GPR30 is more frequently expressed in malignant than benign ovarian endometriotic cysts and correlates with MMP-9 expression

International Journal of Gynecological Cancer

Volumn 22, Issue 4, 2012, Pages 539-545

  Long, Li ^a   Cao, Yi ^a   Tang, Liang Dan ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Endometriosis; Endometriosis associated ovarian carcinoma; GPR30; MMP 9

Indexed keywords

G PROTEIN COUPLED RECEPTOR 30; GELATINASE B; MESSENGER RNA; PEROXIDASE; STREPTAVIDIN;

ADULT; ARTICLE; BENIGN OVARIAN ENDOMETRIOTIC CYST; CANCER STAGING; CONTROLLED STUDY; ENDOMETRIOSIS; ENDOMETRIOSIS ASSOCIATED OVARY CARCINOMA; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; OVARY CARCINOMA; OVARY CYST; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME;

ENDOMETRIOSIS; ENDOMETRIUM; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; OVARIAN CYSTS; OVARIAN NEOPLASMS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84863692973     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e318247323d     Document Type: Article

References (20)

1. Miller BA, Chu KC, Hankey BF, et al. Cancer incidence and mortality patterns among specific Asian and Pacific Islander populations in the U. S. Cancer Causes Control. 2008;19:227-256.
2. Sampson J. Endometrial carcinoma of the ovary, arising in endometrial tissue in that organ. Arch Surg. 1925;10:1-72.
3. Guo DH, Pang SJ, Shen Y. Atypical endometriosis: a clinicopathologic study of 163 cases. Zhonghua Fu Chan Ke Za Zhi. 2008;43:831-834.
4. Guo L, Liu T, Lang J. The malignant potential of ovarian atypical endometriosis. Chin J Pathol. 2001;30:169-172.
5. Nezhat F, Datta MS, Hanson V. The relationship of endometriosis and ovarian malignancy: a review. Fertil Steril. 2008;90:1559-1570.
6. Dong S, Terasaka S, Kiyama R. Bisphenol A induces a rapid activation of Erk1/2 through GPR30 in human breast cancer cells. Environ Pollut. 2011;159:212-218.
7. Smith HO, Arias-Pulido H, Kuo DY, et al. GPR30 predicts poor survival for ovarian cancer. Gynecol Oncol. 2009;114:465-471.
8. He YY, Cai B, Yang YX, et al. Estrogenic G protein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the MEK/ERK mitogen-activated protein kinase pathway. Cancer Sci. 2009;100:1051-1061.
9. Kleuser B, Malek D, Gust R, et al. 17-Beta-estradiol inhibits transforming growth factor-beta signaling and function in breast cancer cells via activation of extracellular signal-regulated kinase through the G protein-coupled receptor 30. Mol Pharmacol. 2008;74:1533-1543.
10. Kwon Y, Cukierman E, Godwin AK. Differential expressions of adhesive molecules and proteases define mechanisms of ovarian tumor cell matrix penetration/invasion. PLoS One. 2011;6:e18872.
11. Scott RB. Malignant changes in endometriosis. Obstet Gynecol. 1953;2:283-289.
12. Brinton L, Gridley M, Persson I, et al. Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol. 1997;176:572-579.
13. Aris A. Endometriosis-associated ovarian cancer: a ten-year cohort study of women living in the Estrie Region of Quebec, Canada. Journal of Ovarian Research. 2010;3:2.
14. Melin A, Sparen P, Bergqvist A. Endometriosis and the risk of cancer with special emphasis on ovarian cancer. Hum Reprod. 2006;21:1237-1242.
15. Olde B, Leeb-Lundberg LM. GPR30/GPER1: searching for a role in estrogen physiology. Trends Endocrinol Metab. 2009;20:409-416.
16. Ariazi EA, Brailoiu E, Yerrum S, et al. The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. Cancer Res. 2010;70:1184-1194.
17. Salerno MG, Masciullo V. Endometrioid adenocarcinoma with squamous differentiation arising from ureteral endometriosis in a patient with no history of gonadal endometriosis. Gynecol Onco. 2005;99:749.
18. Bese T, Simsek Y, Bese N, et al. Extensive pelvic endometriosis with malignant change in tamoxifen-treated postmenopausal women. Int J Gynecol Cancer. 2003;13:376-380.
19. Nomura S, Suganuma T, Suzuki T, et al. Endometrioid adenocarcinoma arising from endometriosis during 2 years of estrogen replacement therapy after total hysterectomy and bilateral salpingo-oophorectomy. Acta Obstet Gynecol Scand. 2006;85:1019-1021.
20. Al Talib A, Gilbert L, Arseneau J. Endometrioid adenocarcinoma 13 years after total abdominal hysterectomy and bilateral salpingo-oophorectomy. Saudi Med J. 2008;29:1044-1047.